|CRDAMC Homepage | CRDAMC Library Phone #: (254) 288-8366 | CRDAMC Library Fax #: (254) 288-8368|
Nicotinamide Adenine Dinucleotide
Nicotinamide adenine dinucleotide (NADH) is an important cofactor, or "assistant," that helps enzymes in the work they do throughout the body. NADH particularly plays a role in the production of energy. It also participates in the production of L-dopa, which the body turns into the important neurotransmitter dopamine.
Based on these basic biochemical facts, NADH has been evaluated as a treatment for jet lag, Alzheimer's disease, Parkinson's disease, chronic fatigue syndrome, depression, and as a sports supplement. However, only the first of these uses has any meaningful scientific evidence behind it, and even that is highly preliminary.
Healthy bodies make all the NADH they need, using vitamin B3 (also known as niacin or nicotinamide) as a starting point. The highest concentration of NADH in animals is found in muscle tissues, which means that meat might be a good source—were it not that most of the NADH in meat is destroyed during processing, cooking, and digestion. In reality, we don't get much NADH from our food.
Therapeutic Dosages TOP
The typical dosage for supplemental NADH ranges from 5 to 50 mg daily, often taken sublingually (under the tongue). Products said to be "stabilized" are available.
Therapeutic Uses TOP
Supplemental NADH has also been proposed as a treatment for Alzheimer's disease, chronic fatigue syndrome, depression, and Parkinson's disease. Additionally, it has additionally been tried as a sports performance enhancer. However, although a few studies have been performed to evaluate these potential uses,2-7 none were designed in such a way as to produce scientifically meaningful results.
What Is the Scientific Evidence for NADH? TOP
In a double-blind, placebo-controlled trial, 35 individuals taking an overnight flight across four time zones were given either 20 mg of NADH or placebo sublingually (under the tongue) on the morning of arrival.8 Participants were twice given tests of wakefulness and mental function: first at 90 minutes and then at 5 hours after landing. Individuals given NADH scored significantly better on these tests than those given placebo.
The only other supporting evidence comes from an unpublished double-blind, placebo-controlled, crossover study funded by the makers of an NADH product.9 In this study, 25 people were kept awake all night and their cognitive function was tested the following day. People given NADH performed significantly better on various measures of mental function than those given placebo. NADH did not, however, reduce daytime sleepiness or enhance mood.
These small but promising studies suggest a need for further research.
Safety Issues TOP
NADH appears to be quite safe when taken at a dosage of 5 mg daily or less. However, formal safety studies have not been completed, and safety in young children, pregnant or nursing women, or those with severe liver or kidney disease has not been established.
References[ + ]
1. Kay GG, Viirre E, Clark J. Stabilized NADH as a countermeasure for jet lag. Presented at: 48th International Congress of Aviation and Space Medicine; September 17-21, 2000; Rio de Janeiro, Brazil.
2. Birkmayer JG, Vrecko C, Volc D, et al. Nicotinamide adenine dinucleotide (NADH)—a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl. 1993;146:32-35.
3. Birkmayer JGD, Birkmayer W. The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent: experience with 205 patients. New Trends Clin Neuropharmacology. 1991;5:19-25.
4. Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci. 1996;26:1-9.
5. Forsyth LM, Preuss HG, MacDowell AL, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999;82:185-191.
6. Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson's disease with NADH. Acta Neurol Scand. 1994;90:345-347.
7. Kuhn W, Muller T, Winkel R, et al. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm. 1996;103:1187-1193.
8. Kay GG, Viirre E, Clark J. Stabilized NADH as a countermeasure for jet lag. Presented at: 48th International Congress of Aviation and Space Medicine; September 17-21, 2000; Rio de Janeiro, Brazil.
9. Moline ML, Rebeta JL, Flye BL, et al. Effectiveness of NADH in alleviating effects of sleep deprivation in healthy middle-aged adults. Abstract presented at: The First International Conference on Mechanisms of Action of Nutraceuticals; October 2001.
Last reviewed December 2015 by EBSCO CAM Review Board
Last Updated: 12/15/2015
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at email@example.com. Our Health Library Support team will respond to your email request within 2 business days.